References
- Taher A, Weatherall D, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–167. Available from: https://pubmed.ncbi.nlm.nih.gov/28774421/
- El-Beshlawy A, Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin. 2009;33(sup1):14–20. Available from: https://pubmed.ncbi.nlm.nih.gov/20001619/
- Chaudhary S, Dhawan D, Prashanth G, et al. Compound heterozygous β+ β0 mutation of HBB gene leading to β-thalassemia major in a Gujarati family: a case study. Mol Genet Metab Rep. 2016;7:51–53. Available from: https://pubmed.ncbi.nlm.nih.gov/27134826/
- Hahalis G, Kremastinos D, Terzis G, et al. Global vasomotor dysfunction and accelerated vascular aging in β-thalassemia major. Atherosclerosis. 2008;198(2):448–457.
- Stoyanova E, Trudel M, Felfly H, et al. Vascular endothelial dysfunction in thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO. PLoS One. 2012;7(6):e38089.
- Ahluwalia N, Genoux A, Ferrieres J, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010;140(4):812–816.
- Cappellini M, Grespi E, Cassinerio E, et al. Coagulation and splenectomy: an overview. Ann N Y Acad Sci. 2005;1054:317–324. Available from: https://pubmed.ncbi.nlm.nih.gov/16339680/
- Mozos I, Jianu D, Gug C, et al. Links between high-sensitivity C-reactive protein and pulse wave analysis in middle-aged patients with hypertension and high normal blood pressure. Dis Markers. 2019;3:1–9. Available from: https://pubmed.ncbi.nlm.nih.gov/31396293/
- Ferrara D, Taylor W. Iron chelation and vascular function: in search of the mechanisms. Arterioscler Thromb Vasc Biol. 2005;25(11):2235–2237. Available from: https://pubmed.ncbi.nlm.nih.gov/16258147/
- Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106(17):2212–2217.
- Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res. 2005;58(2):173–178. Available from: https://pubmed.ncbi.nlm.nih.gov/16055929/
- Gomez D, Baylis R, Durgin B, et al. Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat Med. 2018;24:1418–1429. Available from: https://pubmed.ncbi.nlm.nih.gov/30038218/
- Tunon J, Back M, Badimon L, et al. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice. Eur J Prev Cardiol. 2018;25(9):948–955.
- Ridker P. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320–3331. Available from: https://pubmed.ncbi.nlm.nih.gov/30415883/
- Hartman J, Frishman W. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147–151. Available from: https://pubmed.ncbi.nlm.nih.gov/24618929/
- Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334. Available from: https://pubmed.ncbi.nlm.nih.gov/11466099/
- Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46(5):1118–1122. Available from: https://pubmed.ncbi.nlm.nih.gov/16216991/
- Esteve E, Castro A, Lopez-Bermejo A, et al. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007;30(4):939–945.
- Lee W, Allison M, Kim D, et al. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo study). Am J Cardiol. 2007;99(1):99–102.
- Giugliano G, Brevetti G, Lanero S, et al. Leukocyte count in peripheral arterial disease: a simple, reliable, inexpensive approach to cardiovascular risk prediction. Atherosclerosis. 2010;210(1):288–293.
- Döring Y, Drechsler M, Soehnlein O, et al. Neutrophils in atherosclerosis: from mice to man. Arterioscler Thromb Vasc Biol. 2015;35(2):288–295.
- Hashemi M, Shirzadi E, Talaei Z, et al. Effect of heterozygous beta-thalassemia trait on coronary atherosclerosis via coronary artery disease risk factors: a preliminary study. Cardiovasc J Afr. 2007;18(3):165–168. Available from: https://pubmed.ncbi.nlm.nih.gov/17612748/
- Ricchi P, Ammirabile M, Maggio A. Hypocholesterolemia in thalassemia – pathogenesis, implications and clinical effects. Eur Hematol. 4(4), 20–23. (2010). Available from: https://www.researchgate.net/publication/267962037_Hypocholesterolemia_in_Thalassemia_-_Pathogenesis_Implications_and_Clinical_Effects
- Giardina P, Forget B. Thalassemia syndromes. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. 5th ed. Philadelphia: Elsevier Churchill Livingstone; 2008. p. 535–563.
- Fin A, Kolodgie FD, Virmani R. Correlation between carotid intima-media thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30:177–181.
- Jarvisalo M, Jartti L, Nanto-Salonen K, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation. 2001;104(24):2943–2947.
- Cheung T, Chow P, Chan G, et al. Carotid-intima media thickness is increased and related to arterial stiffness in patients with beta-thalassemia major. Br J Hematol. 135, 732–734. (2006). Available from: https://pubmed.ncbi.nlm.nih.gov/17107355/
- Hahalis G, Kalogeropoulos A, Terzis G, et al. Premature atherosclerosis in non-transfusion-dependent b-thalassemia intermedia. Cardiol. 2011;118(3):159–163.
- Adly A, El-Sherif N, Ismail E, et al. Vascular dysfunction in patients with young β-thalassemia: relation to cardiovascular complications and subclinical atherosclerosis. Clin Appl Thromb Hemost. 2015;21(8):733–744.
- Nassef S, El Shenoufy M, Rawi R, et al. Assessment of atherosclerosis in peripheral and central circulation in adult β-thalassemia intermedia patients by color doppler ultrasound: Egyptian experience. Vasc Res. 57, 206–212. (2020). Available from: https://pubmed.ncbi.nlm.nih.gov/32396894/
- Hartman C, Tamary H, Tamir A. Hypocholesterolemia in children and adolescents with beta-thalassemia intermedia. J Pediatr. 2002;141:543–547.
- Ricchi P, Ammirabile M, Spasiano A, et al. Hypocholesterolemia in adult patients with thalassemia: a link with the severity of genotype in thalassemia intermedia patients. Eur J Hematol. 2009;82(3):219–222.
- Tselepis D, Hahalis G, Tellis C, et al. Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β -thalassemia. J Lipid Res. 2010;51:3331–3341. Available from: https://pubmed.ncbi.nlm.nih.gov/20625038/
- Ragab S, Safan M, Sherif A. Lipid profile in beta-thalassemia children. Menofia Medical J. 27, 66–72. (2014). Available from: https://www.mmj.eg.net/article.asp?=1110-2098;year=2014;volume=27;issue=1;spage=66;epage=72;aulast=Ragab
- Tolba M, Soliman N, El-Kamah G, et al. Oxidative stress damage and risk of atherosclerosis in beta-thalassemia patients. Int J Life Sci Res. 3(4), 73–84. (2015). Available from: https://www.researchgate.net/publication/307820197_Oxidative_Stress_Damage_and_Risk_of_Atherosclerosis_in_Beta-Thalassemia_Patients
- Amendola G, Danise P, Todisco N, et al. Lipid profile in beta-thalassemia intermedia patients: correlation with erythroid bone marrow activity. Int J Lab Hematol. 2007;29:172–176. Available from: https://pubmed.ncbi.nlm.nih.gov/17474893/
- Calandra S, Bertolini S, Pes G, et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia . Semin Vasc Med. 4, 271–278. (2004). Available from: https://pubmed.ncbi.nlm.nih.gov/15630628/
- Cakmak A, Soker M, Koc A, et al. Paraoxonase and arylesterase activity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol. 2009;31(8):583–587.
- Al-Quobaili F, Abou Asali I. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major. Saudi Med J. 2004;25:871–875. Available from: https://pubmed.ncbi.nlm.nih.gov/15235691/
- Haghpanah S, Davani M, Samadi B, et al. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. J Res Med Sci. 2010;15:150–154. Available from: https://pubmed.ncbi.nlm.nih.gov/21526074/
- Aydin S, Eren M, Aydin S, et al. The bioactive peptides salusins and apelin-36 are produced in human arterial and venous tissues and the changes of their levels during cardiopulmonary bypass. Peptides. 2012;37(2):233–239.
- Miller Y, Felikman Y, Shaklai N. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch Biochem Biophys. 1996;326:252–260.
- Altamentova S, Marva E, Shaklai N. Oxidative interaction of unpaired hemoglobin chains with lipids and proteins: a key for modified serum lipoprotein in thalassemia. Arch Biochem Biophys. 1997;345:39–46.
- Safniyat S, Shakibazad N, Haghpanah S, et al. Parameters of tissue iron overload and cardiac function in patients with thalassemia major and intermedia. Acta Hematologica Polonica. 2020;51(2), 95–101. Available from: https://www.researchgate.net/publication/342836867_Parameters_of_tissue_iron_overload_and_cardiac_function_in_patients_with_thalassemia_major_and_intermedia
- Hossaini S, Haeri M. Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator. J Hematopathol. 12, 143–147. (2019). Available from: https://link.springer.com/article/10.1007/s12308-019-00363–x
- Yassin M, Soliman A, De Sanctis V, et al. Final height and endocrine complications in patients with β-thalassemia intermedia: our experience in non-transfused versus infrequently transfused patients and correlations with liver iron content. Mediterr J Hematol Infect Dis. 2019;11(1):e2019026.
- Weatherall DJ. Genetic disorders of hemoglobin. In: Hofbrand AV, Lewis SM, Tuddenham EGD, editors. Postgraduate Hematology 4th ed. Vol. 6. Butterworth: Heinemann; 2000. p. 91–118.
- Akhlaghpoor S, Hoseini M, Jafarisepehr A. Association of iron overload based quantitative T2* MRI technique and carotid intima-media thickness in patients with beta-thalassemia: a cross-sectional study. BMC Cardiovasc Disord. 2010;10:62.
- Cheung Y, Chan G, Ha S. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation. 2002;106(20):2561–2566. Available from: https://pubmed.ncbi.nlm.nih.gov/12427652/
- Ramakrishna G, Rooke T, Cooper L. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med. 2003;8(3):203–210. Available from: https://pubmed.ncbi.nlm.nih.gov/14989563/
- Shah S, Alam M. Role of iron in atherosclerosis. Am J Kidney Dis. 2003;41(Suppl 1):S80–3. Available from: https://pubmed.ncbi.nlm.nih.gov/12612959/
- Abdelsamei H, El-Sherif A, Ismail A, et al. The role of the carotid Doppler examination in the evaluation of atherosclerotic changes in β-thalassemia patients. Mediterr J Hematol Infect Dis. 2015;7:e2015023. Available from: https://pubmed.ncbi.nlm.nih.gov/25745550/
- Tantawy A, Adly A, El Maaty M, et al. Subclinical atherosclerosis in young β -thalassemia major patients. Hemoglobin. 2009;33(6):463–474.
- Oztürk O, Yaylim I, Aydin M, et al. Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia major. 2001. Hematologia (Budap). 31(3), 237–244. Available from: https://pubmed.ncbi.nlm.nih.gov/11855786/
- Del Giudice M, Gangestad S. Rethinking IL-6, and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75.
- Kanavaki I, Makrythanasis P, Lazaropoulou C, et al. Soluble endothelial adhesion molecules and inflammation markers in patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2009;43(3):230–234.
- Aggeli C, Antoniades C, Cosma C, et al. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int J Cardiol. 2005;105(1):80–84.
- Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507–532. Available from: https://pubmed.ncbi.nlm.nih.gov/26117398/
- Kampus P, Kals J, Ristimäe T, et al. High-sensitivity C-reactive protein affects central hemodynamics and augmentation index in apparently healthy persons. J Hypertens. 2004;22(6):1133–1139.
- Kim J, Kang T, Kim J, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis. 2007;192(2):401–406.
- Park S, Lakatta E. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53(2):258–261. Available from: https://pubmed.ncbi.nlm.nih.gov/22318811/
- Nurizal A, Antono D, Wijaia I, et al. Correlation between high-sensitivity C reactive protein and local arterial stiffness measured by radiofrequency echo tracking system in type 2 diabetic patients. Acta Med Indones. 2014;46(4):308–313. https://pubmed.ncbi.nlm.nih.gov/25633547/
- Huang Y, Li J, Chen J, et al. The association of circulating miR-29b and interleukin-6 with subclinical atherosclerosis. Cell Physiol Biochem. 2017;44(4):1537–1544.
- Ridker P, Rifai N, Stampfer M, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–1772.
- Volpato S, Guralnik J, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation. 2001;103(7):947–953.
- Harris T, Ferrucci L, Tracy R, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–512.
- Carbone F, Mach F, Montecucco F. Update on the role of neutrophils in atherosclerotic plaque vulnerability. Curr Drug Targets. 2015;16(4):321–333. Available from: https://pubmed.ncbi.nlm.nih.gov/25382205/
- Ozturk C, Balta S, Balta I, et al. Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behcet disease without cardiovascular involvement. Angiology. 2015;66(3):291–296.
- Prats-Puig A, Gispert-Sauch M, Diaz-Roldan F, et al. Neutrophil-to-lymphocyte ratio: an inflammation marker related to cardiovascular risk in children. Thromb Hemost. 2015;114(4), 727–734. Available from: https://pubmed.ncbi.nlm.nih.gov/26224329/
- Hosokawa T, Kumon Y, Kobayashi T, et al. Neutrophil infiltration and oxidant production in human atherosclerotic carotid plaques. Histol Histopathol. 2011;26(1):1–11. Available from: https://pubmed.ncbi.nlm.nih.gov/21117022/
- Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106(23):2894–2900.
- Guasti L, Dentali F, Castiglioni L, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/ or cardiac revascularisation. A systematic review on more than 34,000 subjects. 2011. Thromb Hemost. 106(4), 591–599. Available from: https://pubmed.ncbi.nlm.nih.gov/21866299/
- Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934–1936. Available from: https://pubmed.ncbi.nlm.nih.gov/14630822/
- Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884. Available from: https://pubmed.ncbi.nlm.nih.gov/17372174/
- Davis B, O’Sullivan C, Jarritt P, et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263–269. Available from: https://pubmed.ncbi.nlm.nih.gov/15001468/
- Wood J, Enriquez C, Ghugre N, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386–395. Available from: https://pubmed.ncbi.nlm.nih.gov/16339687/
- Olivieri N, Brittenham G. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761. Available from: https://pubmed.ncbi.nlm.nih.gov/9028304/
- Olivieri N, Nathan D, MacMillan J, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–578. Available from: https://pubmed.ncbi.nlm.nih.gov/8047081/
- Moghaddam H, Badiei Z, Eftekhari K, et al. Prevalence of pulmonary hypertension in patients with thalassemia intermedia in 2009: a single center’s experience. Electron Physician. 2015;7:1102–1107. Available from: https://pubmed.ncbi.nlm.nih.gov/26388975/
- Amoozgar H, Farhani N, Karimi M. Early echocardiographic findings in β-thalassemia intermedia patients using standard and tissue doppler methods. Pediatr Cardiol. 2011;32:154–159.
- Gladwin M, Kato G. Hemolysis-associated endothelial dysfunction and pulmonary hypertension. Adv Pulm Hypertens Spring. 6, 23–30. (2007). Available from: https://meridian.allenpress.com/aph/article/6/1/23/432022/Hemolysis-Associated-Endothelial-Dysfunction-and
- Habib A, Kunzelmann C, Shamseddeen W, et al. Elevated levels of circulating procoagulant microparticles in patients with b-thalassemia intermedia. Hematologica. 2008;93:941–942. Available from: https://pubmed.ncbi.nlm.nih.gov/18460647/
- Karimi M, Khanlari M, Rachmilewitz E. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am J Hematol. 2008;83:77–79.
- Taher A, Musallam K, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassemia intermedia. Br J Hematol. 150:486–489. (2010). Available from: https://pubmed.ncbi.nlm.nih.gov/20456362/